{"title": "PPT - BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C PowerPoint Presentation - ID:3351175", "author": "Gene", "url": "https://www.slideserve.com/gene/biomarcadores-de-tratamiento-en-la-hepatitis-c", "hostname": "slideserve.com", "description": "BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C. Madrid, 13 de Mayo de 2011. Manuel Romero-G\u00f3mez. Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Digestivas. Hospital Universitario de Valme. Universidad de Sevilla, Sevilla. Respuesta viral sostenida en genotipo 1. D 25% +Riba. D10 % +Peg.", "sitename": "SlideServe", "date": "2014-08-21", "cleaned_text": "440 likes | 559 Views BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C. Madrid, 13 de Mayo de 2011. Manuel Romero-G\u00f3mez. Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Digestivas. Hospital Universitario de Valme. Universidad de Sevilla, Sevilla. Respuesta viral sostenida en genotipo 1. D 25% +Riba. D10 % +Peg. E N D [BIOMARCADORES DE TRATAMIENTO EN LA HEPATITIS C](https://image1.slideserve.com/3351175/biomarcadores-de-tratamiento-en-la-hepatitis-c-l.jpg) Madrid, 13 de Mayo de 2011 Manuel Romero-G\u00f3mez. Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Digestivas. Hospital Universitario de Valme. Universidad de Sevilla, Sevilla. [Respuesta viral [Factores predictivos Respuesta](https://image1.slideserve.com/3351175/factores-predictivos-de-respuesta-l.jpg) Manns MP, et al. Nat Rev Drug Discov. 2007 Fried et al. NEJM 2002 Romero-G\u00f3mez et al. Liver Int 2011 [Genotype](https://image1.slideserve.com/3351175/genotype-l.jpg) et al. Nat Rev Drug Discov. 2007;6:991-1000. Pazienza V et al. Hepatology 2007;45:1164 2. Sheikh MY, et al. Hepatology 2008;47:2127 3. Moucari R et polymorphisms & al. Nature 2009; Thompson et al. Gastro2010; Rauch et al. Gastro 2010;Tanaka Nature Gen 2009; Suppiah et al. Nature SVR & genotype Int 2010 (in press) [IL28B polymorphisms: Distribution by race & SVR](https://image1.slideserve.com/3351175/slide17-l.jpg) Ge et al. Nature 2009; [IL28B mRNA expressionrs8099917](https://image1.slideserve.com/3351175/il28b-mrna-expression-rs8099917-l.jpg) Suppiah et al. 2009;41:1105 action](https://image1.slideserve.com/3351175/inf-l3-il28b-mechanism-of-action-l.jpg) Asselah et [N=731](https://image1.slideserve.com/3351175/slide20-l.jpg) genotipo de la IL28b seg\u00fan RVR Genotipo 1](https://image1.slideserve.com/3351175/influencia-del-genotipo-de-la-il28b-seg-n-rvr-genotipo-1-l.jpg) Thompson A et al. Gastro 2010 Mangia A et al. Gastro 2010 [N=268](https://image1.slideserve.com/3351175/influencia-il28b-en-genotipo-2-3-l.jpg) Genotipo 2/3 rs8099917 N=488 Genotipo 2 rs8099917 Influencia IL28b en genotipo % RVS Yu al. Hepatology 2011;53:7-13 Mangia Gastro 2010 Montes-Cano et al. Hepatology 2010 [Influencia del genotipo de la IL28b seg\u00fan genotipo viral y](https://image1.slideserve.com/3351175/influencia-del-genotipo-de-la-il28b-seg-n-genotipo-viral-y-rvr-l.jpg) RVR Thompson A et al. Gastro 2010 Mangia A et al. Gastro 2010 [IL28b en pacientes tratados con triple terapia:](https://image1.slideserve.com/3351175/slide28-l.jpg) IP + Peg + Riba [SPRINT-2: SVR by IL28B Polymorphism](https://image1.slideserve.com/3351175/sprint-2-svr-by-il28b-polymorphism-l.jpg) % SVR 50 64 63 77 44 55 33 116 67 103 82 115 10 37 23 42 26 44 Poordad et al. EASL 2011 [Triple terapia con boceprevir. ](https://image1.slideserve.com/3351175/slide30-l.jpg) SPRINT-2: RVS en funci\u00f3n PCR w 4 y 8. Estos resultados incluyen exclusivamente pacientes raza no negra. Poordad F, et al. = placebo Data from T12/PR48 and LI T12/PR48 arms were pooled since no differences were observed between TVR arms. Randomization stratified prior response. Stopping rules were applied for TVR (Weeks 4, 6, 8 for T12/PR48, Weeks 8, 10, 12 for LI T12/PR48) and PR (Weeks 12, 24, 36 for T12/PR48, Weeks 16, 24, 3% 20% St\u00e4ttermayer AF et al. CGH 2011 (in press) Mangia et al. Gastro 2010 Romero G\u00f3mez et al. Liver Int 2011 p=ns load Del Campo & lipid and & lipid and = 871) 6.1 5.6 Baseline fibrosis (METAVIR F0-F2 vs F3-F4) 0.1 1.0 10.0 et al. Nature. 2009;461:399-401. [No RVR](https://image1.slideserve.com/3351175/slide43-l.jpg) "}